— Improved loss from operations by 31% — — Acquired SOLOSEC, a commercially attractive, single-dose oral antibiotic FDA-approved to treat two pervasive sexual health infections — — Forged commercial agreement for Phexxi in Middle East — SAN DIEGO , Nov. 14, 2024 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. ("Evofem" or "the Company") (OTCQB: EVFM ) today announced financial results for the third quarter and nine-month period ended September 30, 2024 .
Highlights include: Acquired global rights to SOLOSEC® (secnidazole) 2g oral granules , a single-dose oral antibiotic FDA approved to treat bacterial vaginosis and trichomoniasis, two common sexual health infections. Licensed Phexxi® (lactic acid, citric acid and potassium bitartrate) commercial rights in the Middle East to Emirati pharmaceutical company Pharma 1 Drug Store. The regulatory submission for the hormone-free contraceptive is on track for submission to the UAE Ministry of Health by year-end 2024.
Launched a Market Development Collaboration with Pearsanta focused on its blood-based diagnostic test for endometriosis, a chronic disease associated with severe, life-impacting pain that affects approximately one in ten women of reproductive age. Improved loss from operations to $2.4 million for the third quarter of 2024, versus a loss from operations of $3.
6 million in the prior year quarter. Aditxt, Inc . (Nasdaq: ADTX ) has invested $5.
0 million in Evofem since May 2024 , including $1.3.
